RU2016145596A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016145596A3 RU2016145596A3 RU2016145596A RU2016145596A RU2016145596A3 RU 2016145596 A3 RU2016145596 A3 RU 2016145596A3 RU 2016145596 A RU2016145596 A RU 2016145596A RU 2016145596 A RU2016145596 A RU 2016145596A RU 2016145596 A3 RU2016145596 A3 RU 2016145596A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001188P | 2014-05-21 | 2014-05-21 | |
| US62/001,188 | 2014-05-21 | ||
| PCT/US2015/032069 WO2015179707A1 (en) | 2014-05-21 | 2015-05-21 | Imidazole derivatives as formyl peptide receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016145596A RU2016145596A (ru) | 2018-06-21 |
| RU2016145596A3 true RU2016145596A3 (enrdf_load_stackoverflow) | 2018-11-19 |
| RU2748652C2 RU2748652C2 (ru) | 2021-05-28 |
Family
ID=53276329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016145596A RU2748652C2 (ru) | 2014-05-21 | 2015-05-21 | Производные имидазола как модуляторы формилпептидного рецептора |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| DK2770989T3 (en) | 2011-10-26 | 2018-12-17 | Allergan Inc | AMIDE DERIVATIVES OF N-URINE SUBSTITUTED AMINO ACIDS AS FORMYL Peptide RECEPTOR SIMILAR-1 (FPRL-1) RECEPTOR MODULATORS |
| US20140256685A1 (en) * | 2013-03-06 | 2014-09-11 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| US9926264B2 (en) | 2013-11-21 | 2018-03-27 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| US10301269B2 (en) | 2014-05-21 | 2019-05-28 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
| EP3442950A1 (en) * | 2016-04-12 | 2019-02-20 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| BRPI0416272A (pt) | 2003-11-07 | 2007-01-09 | Acadia Pharm Inc | usos do receptor fprl1, e de compostos, uso profilático de compostos, métodos de triagem para um composto capaz de afetar uma ou mais atividades de um receptor fprl1, de tratamento ou prevenção de inflamação, de identificação de um composto de indução de vasodilatação, para antagonismo de uma resposta vasoconstrutiva a um sulfidopeptìdeo leucotrieno em um indivìduo, e para estimulação de proliferação celular em um indivìduo, e, composto |
| DK1723128T3 (da) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| JP5534811B2 (ja) * | 2006-08-24 | 2014-07-02 | アストラゼネカ アクチボラグ | 増殖性疾患の治療に有用なモルホリノピリミジン誘導体 |
| WO2009000748A1 (en) | 2007-06-27 | 2008-12-31 | Solvay Fluor Gmbh | Preparation of compounds with a perfluoroalkylsulfonyl group |
| JP2010533158A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−９４５ |
| CN101998680B (zh) * | 2009-08-24 | 2016-01-13 | 中兴通讯股份有限公司 | 帧序列号的发送方法及节点b和服务无线网络控制器 |
| WO2012074785A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| EP2673263A1 (en) | 2011-02-11 | 2013-12-18 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| CA2841983A1 (en) | 2011-07-11 | 2013-01-17 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| DK2770989T3 (en) * | 2011-10-26 | 2018-12-17 | Allergan Inc | AMIDE DERIVATIVES OF N-URINE SUBSTITUTED AMINO ACIDS AS FORMYL Peptide RECEPTOR SIMILAR-1 (FPRL-1) RECEPTOR MODULATORS |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| WO2013122953A1 (en) * | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| SG11201406629VA (en) | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| US20140256685A1 (en) | 2013-03-06 | 2014-09-11 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases |
| CA3133264A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| RU2696581C2 (ru) | 2013-07-16 | 2019-08-05 | Аллерган, Инк. | Производные n-мочевинозамещенных аминокислот как модуляторы формил-пептидного рецептора |
| US9926264B2 (en) | 2013-11-21 | 2018-03-27 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| US9604934B2 (en) | 2014-01-29 | 2017-03-28 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9920013B2 (en) | 2014-01-29 | 2018-03-20 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| US10301269B2 (en) | 2014-05-21 | 2019-05-28 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
| WO2017172761A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| EP3442950A1 (en) | 2016-04-12 | 2019-02-20 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
-
2015
- 2015-05-21 US US15/312,367 patent/US10301269B2/en active Active
- 2015-05-21 EP EP15726498.7A patent/EP3145916B1/en active Active
- 2015-05-21 JP JP2016568605A patent/JP6660889B2/ja active Active
- 2015-05-21 DK DK15726498.7T patent/DK3145916T3/da active
- 2015-05-21 CA CA2948876A patent/CA2948876A1/en not_active Abandoned
- 2015-05-21 CN CN201580026983.9A patent/CN106458921B/zh active Active
- 2015-05-21 AU AU2015264021A patent/AU2015264021B2/en active Active
- 2015-05-21 WO PCT/US2015/032069 patent/WO2015179707A1/en active Application Filing
- 2015-05-21 KR KR1020167035670A patent/KR20170005121A/ko not_active Ceased
- 2015-05-21 BR BR112016027133A patent/BR112016027133A8/pt not_active Application Discontinuation
- 2015-05-21 ES ES15726498T patent/ES2788700T3/es active Active
- 2015-05-21 RU RU2016145596A patent/RU2748652C2/ru active
-
2019
- 2019-05-22 US US16/419,317 patent/US10800744B2/en active Active
-
2020
- 2020-05-25 AU AU2020203420A patent/AU2020203420B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170005121A (ko) | 2017-01-11 |
| BR112016027133A2 (pt) | 2017-08-15 |
| ES2788700T3 (es) | 2020-10-22 |
| RU2748652C2 (ru) | 2021-05-28 |
| AU2015264021A1 (en) | 2016-12-01 |
| US10800744B2 (en) | 2020-10-13 |
| CN106458921B (zh) | 2020-03-24 |
| AU2020203420A1 (en) | 2020-06-11 |
| EP3145916A1 (en) | 2017-03-29 |
| US20200115346A1 (en) | 2020-04-16 |
| RU2016145596A (ru) | 2018-06-21 |
| DK3145916T3 (da) | 2020-05-11 |
| JP6660889B2 (ja) | 2020-03-11 |
| WO2015179707A1 (en) | 2015-11-26 |
| EP3145916B1 (en) | 2020-02-12 |
| JP2017520528A (ja) | 2017-07-27 |
| BR112016027133A8 (pt) | 2021-06-29 |
| US20170096401A1 (en) | 2017-04-06 |
| US10301269B2 (en) | 2019-05-28 |
| AU2015264021B2 (en) | 2020-02-27 |
| CN106458921A (zh) | 2017-02-22 |
| AU2020203420B2 (en) | 2021-12-16 |
| CA2948876A1 (en) | 2015-11-26 |